CLGN Form 144: 140,000 Ordinary Shares Proposed Sale via UBS

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd (CLGN) filed a Form 144 notifying a proposed sale of 140,000 ordinary shares through UBS Securities LLC with an aggregate market value of $308,000. The filing lists 12,716,014 shares outstanding and an approximate sale date of 10/10/2025.

The shares were acquired in a private placement from the issuer on 10/27/2019 and payment was by wire transfer in US$ on the same date. The filer certifies no undisclosed material adverse information and reports no sales in the past three months.

Positive

• Brokered sale through UBS Securities LLC, indicating use of an established dealer
• Full payment was made at acquisition by wire transfer on 10/27/2019, showing clear chain of custody

Negative

• Proposed sale equals 140,000 shares, representing a measurable portion of the public float given 12,716,014 shares outstanding
• Aggregate market value is only $308,000, which could pressure near-term liquidity if executed on-market

Insights

Securities Compliance Analyst

Routine insider sale notice; watch aggregate size versus float.

The Form 144 records a proposed brokered sale of $308,000 worth of ordinary shares via UBS Securities LLC on 10/10/2025. The securities were acquired in a private placement on 10/27/2019 and paid for by wire.

The filing is procedural under Rule 144 and includes the filer’s representation that no material undisclosed information exists. Investors and compliance officers should note the sale size relative to the 12,716,014 shares outstanding, which may indicate modest near-term selling supply; monitor actual execution and post-sale holdings within days following the indicated date.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	UBS Securities LLC 1285 Avenue of the Americas New York NY 10019	140000	308000.00	12716014	10/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	10/27/2019	Private placement from Issuer	Collplant Biotechnologies Ltd.			140000	10/27/2019	Wire transfer in US$

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did CollPlant Biotechnologies (CLGN) report in this Form 144?

The filing notifies a proposed sale of 140,000 ordinary shares via UBS Securities LLC with an aggregate market value of $308,000 and an approximate sale date of 10/10/2025.

When were the shares being sold originally acquired for CLGN?

The shares were acquired on 10/27/2019 in a private placement from the issuer, with payment by wire transfer in US$ on that date.

Does the Form 144 show any sales in the past three months for CLGN?

No. The filing states "Nothing to Report" under securities sold during the past three months.

How many shares does CollPlant report outstanding in this filing?

The filing lists 12,716,014 shares outstanding.

Does the filer assert any undisclosed material information in the Form 144?

By signing the notice the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.